Citius Oncology, Inc. (CTOR) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$24.8M, or -$0.34 per diluted share. Operating activities generated -$5.5M of cash. At fiscal year end, Citius Oncology held $100.9M in total assets against $56.1M in total liabilities.
Open the full interactive Citius Oncology financials → Quarterly statements, key ratios, valuation history and price charts.
Citius Oncology Key Stats
| Share Price | $0.79 |
|---|---|
| Market Cap | $85.4M |
| 52-Week Range | $0.49 – $1.79 |
| Shares Outstanding | 107.9 million (basic, 2026 Q3) |
Citius Oncology Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | — | — |
| Operating Income | -$138,115 | -$1.0M | — | -$23.5M |
| Pre-Tax Income | $380,811 | $2.4M | -$20.6M | -$23.7M |
| Income Tax | — | — | $576,000 | $1.1M |
| Net Income | $380,811 | $2.4M | -$21.1M | -$24.8M |
| Diluted EPS | $0.12 | $0.27 | -$0.31 | -$0.34 |
Citius Oncology Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | — | $3.9M | $1.7M | $1.5M |
| Net Income | -$5.0M | -$5.5M | -$26.6M | -$8.9M |
| Diluted EPS | -$0.07 | -$0.06 | -$0.27 | -$0.08 |
Citius Oncology Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Current Assets | $377,344 | $58,200 | $11.0M | $27.5M |
| Total Assets | $68.2M | $72.6M | $84.4M | $100.9M |
| Current Liabilities | $31,836 | $2.0M | $32.7M | $49.5M |
| Total Liabilities | $67.8M | $74.6M | $38.2M | $56.1M |
| Shareholders' Equity | $345,508 | -$2.0M | $46.1M | $44.9M |
Citius Oncology Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$47,968 | -$601,304 | $126,353 | -$5.5M |
| Cash From Investing | -$67.3M | -$1.3M | -$5.0M | -$5.8M |
| Cash From Financing | $67.7M | $1.7M | $4.9M | $15.2M |
Figures from Citius Oncology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Citius Oncology financials page for every line item.
Citius Oncology Company Profile
| Ticker | CTOR |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cranford, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | September 30 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001851484 |
Frequently Asked Questions
What was Citius Oncology's net income in fiscal 2025?
Citius Oncology reported net income of -$24.8M for fiscal 2025.
What was Citius Oncology's earnings per share (EPS) in fiscal 2025?
Citius Oncology's diluted EPS was -$0.34 for fiscal 2025 (adjusted for any later stock splits).
What was Citius Oncology's revenue last quarter?
In its most recent reported quarter (2026 Q3), Citius Oncology reported revenue of $1.5M.
How many shares of Citius Oncology are outstanding?
Citius Oncology reported a weighted average of 107.9 million basic shares outstanding in 2026 Q3.
What is Citius Oncology's market cap?
Based on its latest closing price, Citius Oncology (CTOR) has a market capitalization of about $85.4M.
When does Citius Oncology's fiscal year end?
Citius Oncology's fiscal year end, as registered with the SEC, is September 30.
Where is Citius Oncology headquartered?
Citius Oncology lists its business address in Cranford, New Jersey in its SEC filings.